Analysis of Adverse Reactions Related to Drugs and Vaccines Received at the National Centre for Pharmacovigilance from 2009 to 2016 in Togo
- 1 Département des Sciences Pharmaceutiques, Faculté des Sciences de la Santé, Université de Lomé, Lomé, Togo
- 2 Département des Sciences Pharmaceutiques, Faculté des Sciences de la Santé, Université de Lomé, Lomé, Togo
- 3 Département des Sciences Pharmaceutiques, Faculté des Sciences de la Santé, Université de Lomé, Lomé, Togo
- 4 Département des Sciences Pharmaceutiques, Faculté des Sciences de la Santé, Université de Lomé, Lomé, Togo
- 5 Département des Sciences Pharmaceutiques, Faculté des Sciences de la Santé, Université de Lomé, Lomé, Togo
- 6 Département des Sciences Pharmaceutiques, Faculté des Sciences de la Santé, Université de Lomé, Lomé, Togo
- 7 Direction de la Pharmacie, du Médicament et des Laboratoires, Ministère de la Santé et de la Protection Sociale, Lomé, Togo
- 8 Comité de Bioéthique et de la Recherche en Santé, Ministère de la Santé et de la Protection Sociale, Lomé, Togo
Abstract
Objectives: To assess the received suspected adverse events occurring upon treatment with drugs and vaccines, at National Centre for Pharmacovigilance, in Togo, from 2009 to 2016. Methods: A crossover study was conducted in order to collect data about patients, drugs, suspected adverse events and notifiers. Suspected adverse events were classified using Med DRA 19.1. Notification’s circumstances were classified into Public Health Programs’ campaigns and routine practice. Data were collated into Excel spreadsheet and processed with SPSS software. Key Findings: Regional distribution is irregular. Of the 322 collected report forms, paramedics have notified 60.8% of the cases. Adult patients were the most represented (70.2%). Public Health Programs campaigns provided 72.6% versus 27.4% for routine practice including Neglected Tropical Diseases (41.4%), immunization (27.7%), tuberculosis (25.9%) and 4.5% for HIV. Skin disorders were the most prevalent suspected adverse events (147 sheets; 45.7%) followed by general disorders and administration site disorders (29.8%) and gastro-intestinal disorders (12.7%). General anti-infective drugs for systemic use, antiparasites, and insecticides were the most reported class of medications (161 sheets; 44.7%). Conclusions: A thorough follow-up of pharmacovigilance launched activities is needed to build a sustainable adverse effect’s surveillance system and routine practice has to be strengthened.
- European Medicines Agency (2017) Guideline on Good Pharmacovigilance Practices (GVP). Annex I—Definitions (Rev 4). EMA/876333/2011 Rev 4, 22. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC5001 43294.pdf
- Pajot, F. (2005) Objectifs et méthodes du suivi post-commercialisation d’un médicament. Thèse, Université de Nantes, Faculté de pharmacie, Nantes, 101 p.
- Ampadu, H., Hoekman, J., de Bruin, M.L., Pal, S.N., Olsson, S., Sartori, D., Leufkens, H.G.M. and Dodoo, A.N.O. (2016) Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase. Drug Safety, 39, 335-345. https://doi.org/10.1007/s40264-015-0387-4
- Centre National de Pharmacovigilance Togo (2011) Trimester Activities Report 4.
- WHO (2018) Formulaire de notification des manifestations postvaccinales indésirables (MAPI). http://www.who.int/vaccine_safety/initiative/tools/AEFI_reporting_form_FR_Jan2016.pdf?ua=1
- WHO (2012) Assurer la sécurité des interventions de chimioprévention pour la lutte contre les maladies tropicales négligées: Conseils pratiques à l’intention des administrateurs de programmes nationaux sur la prévention, le dépistage, et la prise en charge des événements indésirables graves. 58. http://apps.who.int/iris/bitstream/handle/10665/75185/9789242502190_fre.pdf;jsessionid=20B5 EEA5A262BED2BBB12288E8011BB8?sequence=1
- WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health (2018) ATC/DDD Principles. https://www.whocc.no/atc/structure_and_principles/
- World Health Organization (2018) Essential Medicine and Products. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/
- Bencheikh, R.S., Ouledghriss, R., Skalli, S. and Alj, L. (2018) Pharmacovigilance Systems in Africa North Africa/Sub-Saharan Africa. https://www.dndi.org/wp-content/uploads/2009/11/r_soulaymani_pharmacovigilance-Africa_ast mh2009.pdf
- Kiguba, R., Karamagi, C., Waako, P., Ndagije, H.B. and Bird, S.M. (2014) Recognition and Reporting of Suspected Adverse Drug Reactions by Surveyed Healthcare Professionals in Uganda: Key Determinants. BMJ Open, 4, e005869. https://doi.org/10.1136/bmjopen-2014-005869
- Carbonin, P., Bernabei, R. and Sgadari, A. (1991) Is Age an Independent Risk Factor of Adverse Drug Reactions in Hospitalized Medical Patients? Journal of the American Geriatrics Society, 39, 1093-1099. https://doi.org/10.1111/j.1532-5415.1991.tb02875.x